Menu utilisateur

Accès à distance ? S'identifier sur le proxy UCLouvain

Rechercher

Affichage: 8 résultats.
    • Article de périodique
    Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial
    Jehn, U. Suciu, Stefan[UCL] Thomas, X. Lefrere, F. Muus, P. Berneman, Z. Marie, J-P Adamo, F. Fillet, G. Nobile, F. Ricciuti, F. Leone, G. Rizzoli, V. Montanaro, M. Beeldens, F. Fazi, P. Mandelli, F. Willemze, R. de Witte, T. Amadori, S. (2006) Leukemia — Vol. 20, no. 10, p. 1723-1730 (2006)
    • Communication
    Allogeneic SCT planned in CR-1 after intensive chemotherapy in patients with bad prognosis MDS results in better outcome in the intermediate/high-risk cytogenetic group: a study by the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukemia Groups
    de Witte, T. Hagemeijer, Anne Suciu, Stefan[UCL] Belhabri, A Delforge, Michel Aul, C Aivado, M Selleslag, D. Schouten, H Ferrant, Augustin[UCL] Biersack, H Amadori, S. Muus, P. Jehn, U. Beeldens, F. Jansen, J Hellstrom-Lindberg, P Ossenkoppele, G Gratwohl, A. Marie, JP Willemze, R. (2006) 32nd Annual Meeting of the European-Group-for-Blood-and-Morrow-Transplantation/22nd Meeting of the EBMT-Nures-Group/5th Meeting of the EMBT-Data-Management-Group — Hamburg (Germany)
    • Article de périodique
    The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921)
    Oosterveld, M Ferrant, Augustin[UCL] Suciu, Stefan[UCL] Verhoef, G. Labar, B. Belhabri, A Aul, C Selleslag, D. Wijermans, P Mandelli, F. Amadori, S. Jehn, U. Muus, P. Zittoun, R Hess, U. Anak, O Beeldens, F. Willemze, R. de Witte, T. (2003) Leukemia — Vol. 17, no. 5, p. 859-868 (2003)
    • Article de périodique
    Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CRI): an intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial
    Suciu, Stefan[UCL] Mandelli, F. de Witte, T. Zittoun, R Gallo, E Labar, B. De Rosa, G Belhabri, A Giustolisi, R Delarue, R. Liso, V Mirto, S Leone, G. Bourhis, JH Fioritoni, G Jehn, U. Amadori, S. Fazi, P. Hagemeijer, Anne[UCL] Willemze, R. (2003) Blood — Vol. 102, no. 4, p. 1232-1240 (2003)
    • Article de périodique
    The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial
    Keating, S Suciu, Stefan[UCL] de Witte, T. Zittoun, R Mandelli, F. Belhabri, A Amadori, S. Fibbe, W Gallo, E Fillet, G. Varet, B. Meloni, G Hagemeijer, Anne[UCL] Fazi, P. Solbu, G Willemze, R. (2003) Leukemia — Vol. 17, no. 1, p. 60-67 (2003)
    • Communication
    Intensive chemotherapy versus autologous or allogeneic stemcell transplantation for the treatment of patients with poor risk MDS and secondary AML-A joint study of the Eortc, Ebmt, Hovon, Swiss, Scandinavian and Gimema leukemia groups: A biomed-2 EU-project.
    deWitte, TM Ferrant, Augustin[UCL] Suciu, Stefan[UCL] Anak, O Hagemeijer, Anne[UCL] Selleslag, D. Delforge, Michel[UCL] Belhabi, A Schouten, H Gratwohl, A. Aul, C Aivado, M Amadori, S. Muus, P. Tigaud, I. Jotterand-Bellomo, M Willemze, R. (1999) —
    • Article de périodique
    Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS
    de Witte, T. Ferrant, Augustin[UCL] Suciu, Stefan[UCL] Verhoef, G. Labar, B. Archimbaud, E. Aul, C Selleslag, D. Wijermans, P Mandelli, F. Amadori, S. Jehn, U. Muus, P. Boogaerts, M. Zittoun, R Gratwohl, A. Zwierzina, H Hagemeijer, Anne[UCL] Willemze, R. (2001) Blood — Vol. 98, no. 8, p. 2326-2331 (2001)
    • Article de périodique
    Centre effect on treatment outcome for patients with untreated acute myelogenous leukaemia? An analysis of the AML 8A study of the Leukemia Cooperative Group of the EORTC and GIMEMA
    Keating, S de Witte, T. Suciu, Stefan[UCL] Mandelli, F. Damasio, E Willemze, R. Morra, E. Amadori, S. Dardenne, M Vegna, ML Zittoun, RA (1999) European Journal of Cancer — Vol. 35, no. 10, p. 1440-1447 (1999)